Home › Diagnosis and treatment › Stage 4
Diagnosis & treatment
Stage 4, and if cancer returns
This site is written from a surgeon’s chair, and stage 4 breast cancer, also called metastatic, is treated by the medical oncology team rather than by surgery. This page is here so that the words are not strangers, and so that you know where the fuller answers are.
What stage 4 breast cancer means
Stage 4 means the cancer has spread beyond the breast and nearby nodes to somewhere else, most often bone, lung, or liver. It can be found at the first diagnosis, or years after treatment for an earlier stage. It is treated as a long-term condition with medicine chosen by receptor type, and many of the newest breast cancer medicines are for exactly this situation. Surgery on the breast is sometimes part of the plan, but the plan is led by your medical oncologist.
If breast cancer comes back
Recurrence means cancer that has come back after treatment. It can come back in the same breast or the scar, in the nearby nodes, or elsewhere in the body. The first two are treated much like a new cancer, with surgery, sometimes radiation if it was not used before, and medicine. The workup starts with a new biopsy, because receptors can change from the original cancer.
How metastatic breast cancer is treated
Metastatic breast cancer, or stage 4, is cancer that has reached another organ. It is treated differently from early breast cancer. The aim shifts from removing the cancer to controlling it, for as long as possible and with as good a quality of life as possible. People live with it for years.
The national treatment guidelines for this situation are detailed and they change often as new drugs arrive. In broad terms, treatment is chosen by the same receptor status described above, by what has already been tried, and by how long ago. Endocrine therapy combined with a class of drugs called CDK4/6 inhibitors is the usual first approach for hormone receptor positive, HER2-negative disease. If the cancer has reached bone, a bone-strengthening medicine is added. Supportive care, symptom control, and the option of a clinical trial are treated as part of the plan from the beginning rather than as a last resort.
This site does not attempt to reproduce those guidelines. If you or someone you love is in this situation, the current recommendations are published in full and free of charge by the National Comprehensive Cancer Network, and NCCN also publishes plain-language versions written for patients.
Questions to bring to your appointment
These are the questions that come up most often at a first appointment, whatever the diagnosis. Bring someone with you if you can, and it is fine to ask the same question twice.
Where this comes from
This page is written in plain language from the current NCCN Guidelines for Patients: Invasive Breast Cancer (2026 edition, based on NCCN Guidelines for Breast Cancer version 2.2026), which Dr. Perkins shared as the reference for this page and which is free to read at NCCN.org/patientguidelines, along with NCCN's separate patient guides for DCIS and for metastatic breast cancer. NCCN's material is copyrighted and nothing here reproduces it; readers who want the full detail should go to the source. Breastcancer.org publishes a free guide to reading a pathology report, updated June 2026, at breastcancer.org/pathology-report. Margin definitions follow the Society of Surgical Oncology and American Society for Radiation Oncology consensus statements for invasive cancer (2014) and DCIS (2016). Receptor cutoffs follow the American Society of Clinical Oncology and College of American Pathologists guidelines. Staging follows the American Joint Committee on Cancer, eighth edition. Every clinical statement on this page is listed on the site's verification ledger, and Dr. Perkins read the site on 13 September 2026.
This page is education. It does not diagnose, and the summary it builds is not a treatment plan. Your plan is made with your own care team from your own results.
Published 7 September 2026 as part of the guide; a page of its own since 9 September 2026.